Testing trastuzumab deruxtecan in HER2-zero breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must be advanced (unresectable or metastatic) and all previous biopsies must show HER2-zero (no HER2 protein detected).
- For HR-positive cancer: you must have already tried and not responded to a CDK4/6 inhibitor plus hormone therapy. For HR-negative cancer: you must have had at least one prior treatment for metastatic disease.
- You cannot have received any prior HER2-targeted therapy (such as trastuzumab or trastuzumab deruxtecan).
- You need good organ function (heart, kidney, liver, and blood counts) and no serious lung problems like interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a drug called trastuzumab deruxtecan for people with advanced HER2-positive cancer of the esophagus, stomach, or gastroesophageal junction who haven't had prior systemic treatment for metastatic disease. The drug may help shrink tumors by targeting the HER2 protein and delivering chemotherapy directly to cancer cells.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.